These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 5913764)
1. Alkeran and multiple myeloma. Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764 [No Abstract] [Full Text] [Related]
2. [Treatment of Kahler's disease]. Foa J; Carcassonne Y Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874 [No Abstract] [Full Text] [Related]
3. [Acute leukemia and myeloma]. Riedler GF; Vorburger E; Maier C Schweiz Med Wochenschr; 1972 Nov; 102(44):1592-4. PubMed ID: 4509370 [No Abstract] [Full Text] [Related]
4. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882 [TBL] [Abstract][Full Text] [Related]
5. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)]. Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509 [No Abstract] [Full Text] [Related]
6. [Treatment of multiple myeloma with melphalan: 35 personal cases]. Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260 [No Abstract] [Full Text] [Related]
8. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Lee BJ; Sahakian G; Clarkson BD; Krakoff IH Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771 [No Abstract] [Full Text] [Related]
9. [Clinical aspects of multiple myeloma and its treatment based on a 10-year clinical experience]. Bach I Orv Hetil; 1972 Apr; 113(17):981-5. PubMed ID: 5022591 [No Abstract] [Full Text] [Related]
10. Chemotherapy of multiple myeloma. Ungaro P J Ky Med Assoc; 1973 Dec; 71(12):805-7. PubMed ID: 4766737 [No Abstract] [Full Text] [Related]
11. [Therapy of myeloma]. Sonntag RW Dtsch Med Wochenschr; 1977 Sep; 102(36):1289-91. PubMed ID: 902591 [No Abstract] [Full Text] [Related]
12. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535 [TBL] [Abstract][Full Text] [Related]
13. [Rules of current therapy in multiple myeloma]. Sonntag RW Schweiz Med Wochenschr; 1973 Sep; 103(38):1324-9. PubMed ID: 4763749 [No Abstract] [Full Text] [Related]
14. [Acute leukemia in a case of multiple myeloma]. van Hove W; Hamers J Ned Tijdschr Geneeskd; 1973 Sep; 117(39):1462-5. PubMed ID: 4522766 [No Abstract] [Full Text] [Related]
16. Current management of multiple myeloma. Korst DR Wis Med J; 1968 Nov; 67(11):566-8. PubMed ID: 5747569 [No Abstract] [Full Text] [Related]
17. Alkeran (Melphalan) in the treatment of myelomatosis. Drivsholm A; Videbaek A Acta Med Scand Suppl; 1966; 445():187-93. PubMed ID: 5219910 [No Abstract] [Full Text] [Related]
18. [Intermittent low dose melphalan and prednisone in multiple myeloma]. Yalon M; Levo Y; Many A; Ramot B Harefuah; 1977 Apr; 92(7):296-8. PubMed ID: 863310 [No Abstract] [Full Text] [Related]
19. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents. Ringborg U; Lewensohn R Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439 [TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of multiple myeloma. Review of the recent trials]. Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807 [No Abstract] [Full Text] [Related] [Next] [New Search]